Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2017 Q2- Text added to 2017 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
8th grade Avg
|
New words:
atezolizumab, attributable, avelumab, Bavencio, comprise, David, deliver, Dutch, elicit, EMD, fashion, Frederick, Genentech, Grisewood, helper, highest, HLA, Hoang, immunotherapeutic, investor, ipilimumab, Joshua, justification, law, leader, Mark, mixing, nivolumab, path, payroll, pembrolizumab, Peter, primary, quality, Reddish, remission, Serono, Sherry, Silverman, team, Tecentriq, type, unregistered, Wasserman
Removed:
certainty, economy, effected, impacted, pathway, performed, professional, restated, retroactively, stabilize, suffered, uncertainty
Valuein 2017 Q2 filing- Value in 2017 Q3 filing
Original filings
Filing view